Outlook Therapeutics Braces for a Five-Day Gauntlet: Shareholder Vote on Survival Followed by FDA Decision on ONS-5010

July is shaping up as a binary-riddled month for the small-cap biopharma. Two weeks after shareholders cast decisive ballots on the company’s capital structure, the US Food and Drug Administration will hand down its verdict on ONS-5010, Outlook Therapeutics’ lead ophthalmology candidate for wet age-related macular degeneration. With just $7.7 million in the bank as of March and management openly flagging “substantial doubt” about the company’s ability to continue, both events carry existential weight.

The more immediate crunch comes on July 16, when stockholders vote on a sweeping recapitalization package. The board is asking for authorization to increase the number of shares to 600 million and permission to execute a reverse stock split of up to 1-to-50. The move would dilute existing holders severely but is framed as the only alternative to a far grimmer contingency plan. If the vote fails, management has warned of immediate staff reductions, halted development programs and, in the worst case, a bankruptcy filing.

The urgency of the shareholder meeting was underscored by the company’s recent brush with delisting. Outlook Therapeutics fell below the $1 minimum bid price in February and only clawed its way back to Nasdaq compliance after ten consecutive trading sessions above that threshold. The shares closed at $1.45 on July 2, down roughly 14.2% from the $1.69 level at the start of that week — a retreat analysts attribute to profit-taking after a steep rally that followed a successful regulatory appeal in May.

That rally was triggered by the FDA’s Office of New Drugs siding with Outlook Therapeutics in a Formal Dispute Resolution process, effectively overturning earlier concerns about the clinical data package for ONS-5010. The agency subsequently classified the resubmission as Class 1, meaning a truncated 60-day review cycle and a binding PDUFA date of July 29. The remaining technical questions now center on labeling, manufacturing and quality control, rather than efficacy.

Should investors sell immediately? Or is it worth buying Outlook Therapeutics?

Despite the cash burn, the largest shareholder has stepped in to provide a lifeline. In late May, GMS Ventures invested roughly $5 million through a direct placement, acquiring more than 8 million new shares. Separately, the company lowered the exercise prices of existing warrants to encourage conversion. Still, the balance sheet remains stretched. BTIG has downgraded the stock to Neutral, noting that any potential approval gains already appear priced in.

On the commercial side, Outlook Therapeutics has not been idle. ONS-5010 is already approved in Germany, Austria and the UK, and a recent distribution agreement with Mediconsult AG aims to strengthen its footprint in the DACH region. In the US, the company has secured a partnership with Cencora for logistics and distribution, positioning itself for a potential launch later this year. If the FDA gives the green light, Outlook Therapeutics would become the first company to market an approved ophthalmic bevacizumab formulation for retinal diseases in the United States.

The stock has been nothing short of volatile. The annualized 30-day swing stands at a staggering 227%, while average daily volume has hovered around 5 million shares as institutional and retail investors alike position for binary outcomes. The shareholder vote on July 16 will either unlock the capital needed to survive or trigger a disorderly collapse. Two weeks later, the FDA will decide whether that survival is worth anything at all.